dev roident: the chad mouse | builder @desciatoms @purrptide
🔬
Joined October 2022
- Tweets814
- Following1.9K
- Followers1.2K
- Likes6.9K
steady☯️ retweeted
🐱 Purrptide News · October 31, 2026
🔥 Semaglutide: Lowers Mortality in Diabetic Hemodialysis
💊 Peptide: Semaglutide, Liraglutide · 🏷️ Endocrinology
📌 Target Trial of Semaglutide Versus Dulaglutide or Liraglutide in Patients Receiving Hemodialysis.
👥 Dustin Le, Evan Forman, Walter K Kraft
📅 2026-10-27 · PubMed
🔍 Summary:
Semaglutide was associated with lower mortality and hospitalization rates compared to dulaglutide or liraglutide in patients with diabetes receiving hemodialysis. Body weight loss was also higher with semaglutide.
🤖 AI Analysis:
New research suggests that semaglutide may be a more effective treatment option than dulaglutide or liraglutide for patients with diabetes undergoing hemodialysis. This could lead to improved health outcomes for these patients.
📊 Evidence: Moderate (Clinical study)
📊 Quality Score: ████████░░ 8/10
├ Evidence strength: ██████░░░░ Cohort Study
├ Actionability: ██████░░░░ Actionable
└ Scientific impact: ███████░░░ Moderate
🔗 Read study doi.org/10.64898/2026.09.06.…
Sent by Purrptide Signal · purrptide.com/news
steady☯️ retweeted
solana:5tCju6YNxHq5zrA6tGndr6F7TK42mpUFmeE31cSFpump gaining momentum. $squatcat gaining eternal health.
buy $squatcat gain solana:5tCju6YNxHq5zrA6tGndr6F7TK42mpUFmeE31cSFpump @LaunchOnSF
🤖 Made with AI
Crypto guys are unhealthy. I am one of them. So I built a squat app for @solanamobile
squatcat live on the Solana dApp Store seekertracker.com/dapps/com.…
2
173
steady☯️ retweeted
Daily reminder $NDT presale is live!
Backed by @BioProtocol
And @beakerdao
Join the ignition sale: app.bio.xyz/agents/neurolab-…
Just 2 days and 8 hours left to join before it closes!
$DRUGS ripping
⚛️ DeSci Atoms Market Update 14 September 2026
MarketCap 24hrs Top Gainers
1. Big Pharmai ( $DRUGS ) @Big_Pharmai +165.05%
2. Cerebrum DAO Token ( $NEURON ) +158.00% @Cerebrum_DAO
3. MeAI ($ MEAI) +145.03% @meai_app
Overall DeSci Atoms Marketcap
Total Market Cap: $458,238,885.00 -2.07%
Total 24hrs Volume: $1,501,485.22 +765.04%
1
162
In this study, epitalon suggests an effect on "late-life robustness" rather than just slowing early mortality. Same average life, but longer maximum (more interesting than just a raw “+12% lifespan” headline)
🐱 Purrptide News · September 11, 2026
🔥 Epitalon: Increases Maximum Lifespan by 12%
💊 Peptide: Epitalon, Epithalamin · 🏷️ Peptides
📌 Epitalon and Epithalamin in Regenerative and Longevity Medicine: Mechanisms, Evidence, and Translational Gaps
👥 Ankur Jain, David Gallacher, Mohammed A. Issa
📅 2026-09-09 · Preprints.org
🔍 Summary:
Epitalon, a synthetic tetrapeptide, has been found to increase maximum lifespan by 12.3% in female mice and activate telomerase in human cell lines, potentially contributing to its regenerative and longevity effects. However, human evidence remains limited and inconclusive.
🤖 AI Analysis:
New research on epitalon, a synthetic peptide, shows promise for increasing lifespan and promoting regenerative processes, but more human studies are needed to confirm its effects. Epitalon has been found to activate telomerase in human cell lines and increase maximum lifespan in female mice.
📊 Evidence: Preliminary (Small/Observational)
📊 Quality Score: ██████░░░░ 6/10
├ Evidence strength: ████░░░░░░ Preliminary
├ Actionability: ██░░░░░░░░ Research Only
└ Scientific impact: ██████░░░░ Moderate
🔗doi.org/10.20944/preprints20…
Sent by Purrptide Signal · purrptide.com/news
2
148
Until now, GHK-Cu was mostly discussed in dermatology, cosmetic science, or basic research circles.
This paper places GHK-Cu specifically in the context of regenerative aesthetic medicine, (aimed at surgeons and aesthetic practitioners) rather than just skincare formulators.
🐱 Purrptide News · August 22, 2026
🔥 GHK-Cu: New Peptide Shows Promise in Regenerative Aesthetic Medicine
💊 Peptide: GHK-Cu · 🏷️ Peptides
📌 The Regenerative Potential of GHK-Cu in Aesthetic Medicine
👥 Jonathan Mokhtar, Basel Mohamad, Jewel Haddad
🏛️ @MayoClinic
📅 2026-08-19 · Aesthetic Surgery Journal
🔍 Summary:
GHK-Cu, a peptide, has shown potential in regenerative aesthetic medicine by enhancing collagen synthesis, reducing inflammation, and improving skin appearance. However, most of the evidence comes from preclinical studies, with only two small randomized controlled trials.
🤖 AI Analysis:
A new peptide called GHK-Cu is being studied for its potential to regenerate skin and reduce signs of aging. While the results are promising, more research is needed to confirm its effectiveness.
📊 Evidence: Preliminary (Small/Observational)
📊 Quality Score: ██████░░░░ 6/10
├ Evidence strength: ████░░░░░░ Preliminary
├ Actionability: ███░░░░░░░ Moderate
└ Scientific impact: ██████░░░░ Moderate
🔗doi.org/10.1093/asj/sjag169
Sent by Purrptide Signal · purrptide.com/news
1
4
217
steady☯️ retweeted
🐱 Purrptide News · August 13, 2026
🔥 HCGRec: AI Recommendation Revolution
💊 Peptide: HCG · 🏷️ Artificial Intelligence
📌 HCGRec: Hint-Conditioned Generative Recommendation with Semantic IDs
👥 Kangning Zhang, Haotian Fang, Xukun Luo, Hao Yin, Yang Gao, Peng Yan, Weiwen Liu, Weinan Zhang, Yong Yu
📅 2026-08-13 · arXiv
🔍 Summary:
Researchers developed a new framework called HCGRec that improves the performance of generative recommendation systems by providing hints to the model when it is struggling to generate the correct item. This approach substantially improves over existing methods, reducing the number of uninformative training samples.
🤖 AI Analysis:
A new AI framework called HCGRec is making waves in the world of recommendation systems, improving performance and reducing errors. This could mean more accurate suggestions for you online. The future of online shopping and entertainment just got a whole lot brighter.
📊 Evidence: Preliminary (Small/Observational)
📊 Quality Score: ████░░░░░░ 4/10
├ Evidence strength: ██░░░░░░░░ Preliminary
├ Actionability: ██░░░░░░░░ Research Only
└ Scientific impact: ██████░░░░ Moderate
🔗 arxiv.org/abs/2608.11980
Sent by Purrptide Signal · purrptide.com/news
steady☯️ retweeted
🐱 Purrptide News · August 12, 2026
🔥 Triptorelin: Effective Treatment for Central Precocious Puberty
💊 Peptide: Triptorelin · 🏷️ Pediatric Endocrinology
📌 NHẬN XÉT HIỆU QUẢ ĐIỀU TRỊ CỦA THUỐC TRIPTORELIN 3 THÁNG Ở TRẺ DẬY THÌ SỚM TRUNG ƯƠNG TẠI BỆNH VIỆN NHI TRUNG ƯƠNG NĂM 2018 - 2023
👥 Thị Phương Lan Nguyễn, Thị Huyền Nguyễn, Thị Kim Cúc Trần
📅 2026-08-10 · Tạp chí Y học Việt Nam
🔍 Summary:
Triptorelin, a medication, effectively treats central precocious puberty in girls, slowing down bone growth and improving physical characteristics. The 3-month formulation showed significant benefits after 6 months of treatment.
🤖 AI Analysis:
New hope for children with central precocious puberty, a condition that accelerates physical development. A recent study found that triptorelin treatment can slow down bone growth and improve physical characteristics.
📊 Evidence: Preliminary (Small/Observational)
📊 Quality Score: ██████░░░░ 6/10
├ Evidence strength: ████░░░░░░ Observational
├ Actionability: ██████░░░░ Moderate
└ Scientific impact: ██████░░░░ Moderate
🔗doi.org/10.51298/vmj.v562i1.…
Sent by Purrptide Signal · purrptide.com/news
Learned about an interesting peptide: FOXO4-DRI
Unlike chemo, which basically nukes all fast-growing cells (healthy ones included), FOXO4-DRI is super targeted.
It acts like a sniper that only takes out "zombie cells" while leaving your healthy cells completely untouched.
Not yet proven in humans.
🐱 Purrptide News · August 5, 2026
🔥 FOXO4-DRI: New Hope for Cancer Recurrence Reduction
💊 Peptide: Foxo4-DRI · 🏷️ Oncology
📌 FOXO4-DRI as a Unified Cancer Platform: A Proposed Framework for Prevention, Treatment, and Stopping Cancer from Coming Back
👥 Cameron Goodman
📅 2026-08-04 · Zenodo (CERN European Organization for Nuclear Research)
🔍 Summary:
Researchers propose a unified cancer platform using FOXO4-DRI to clear therapy-induced senescent cancer cells after chemotherapy, which could potentially cut cancer recurrence rates. This platform also aims to directly kill cancer cells and prevent cancer by maintaining near-zero senescent cell burden starting in early adulthood.
🤖 AI Analysis:
A new compound called FOXO4-DRI may hold the key to reducing cancer recurrence rates by targeting senescent cancer cells. Researchers propose a unified cancer platform using this compound to improve treatment outcomes. This innovative approach could change the face of cancer treatment.
📊 Evidence: Preliminary (Small/Observational)
📊 Quality Score: ██████░░░░ 6/10
├ Evidence strength: ██░░░░░░░░ Preliminary
├ Actionability: ████░░░░░░ Moderate
└ Scientific impact: ████████░░ High
🔗 Read study
Sent by Purrptide Signal · purrptide.com/news
3
143
steady☯️ retweeted
This Week's Top Peptide Breakthroughs curated by Purrptide 🔬 purrptide.com
🥇S14G-humanin (HNG) ameliorates diabetic nephropathy tubular injury by inhibiting Z-DNA/ZBP1-mediated necroptosis
sciencedirect.com/science/ar…
🥈Pharmacologic Treatments for MASLD: A Review of Efficacy and Safety Considerations
journals.sagepub.com/doi/10.…
🥉Humanin peptide ameliorates reproductive dysfunction and restores neuroendocrine mechanisms in SSRI-treated male rats
sciencedirect.com/science/ar…
steady☯️ retweeted
🐱 Purrptide News · July 25, 2026
🔥 RetaBase: New Database Unlocks Retatrutide Research
💊 Peptide: Retatrutide · 🏷️ Longevity
📌 RetaBase: a transparent, auto-updating evidence database for retatrutide and related bioactives
👥 Samuel Rosenberg
📅 2026-07-19 · Open MIND
🔍 Summary:
RetaBase is a database that provides a transparent, auto-updating overview of the biomedical literature on retatrutide and related bioactive molecules, allowing for easy browsing and filtering of evidence. The database scores each paper for study quality and translational directness.
🤖 AI Analysis:
Imagine having all the latest research on retatrutide and related compounds at your fingertips. Introducing RetaBase, a game-changing database that's about to revolutionize the way we approach longevity research. Get ready to unlock new discoveries and insights.
📊 Evidence: Preliminary (Small/Observational)
📊 Quality Score: ████░░░░░░ 4/10
├ Evidence strength: ██░░░░░░░░ Preliminary
├ Actionability: ██░░░░░░░░ Research Only
└ Scientific impact: ████░░░░░░ Incremental
🔗github.com/samrosenberg425/R…
Sent by Purrptide Signal · purrptide.com/news
steady☯️ retweeted
🐱 Purrptide News · July 21, 2026
🔥 Semaglutide: Improves Liver Fibrosis
💊 Peptide: Semaglutide · 🏷️ Pharmacology
📌 Pharmacologic Treatments for MASLD: A Review of Efficacy and Safety Considerations
👥 Jonathan S. Newsome
📅 2026-07-20 · Journal of Pharmacy Technology
🔍 Summary:
Semaglutide and resmetirom have shown the most consistent evidence for improving histologic features in metabolic dysfunction-associated steatotic liver disease (MASLD), including statistically significant improvement in fibrosis. These treatments may offer benefits for patients with MASLD, particularly those with fibrosis.
🤖 AI Analysis:
New research highlights the potential of semaglutide and resmetirom in treating metabolic dysfunction-associated steatotic liver disease. These pharmacologic treatments have shown promise in improving histologic features and reducing fibrosis. This breakthrough could offer new hope for patients with limited treatment options.
📊 Evidence: Moderate (Clinical study)
📊 Quality Score: ████████░░ 8/10
├ Evidence strength: ██████░░░░ Clinical Trial
├ Actionability: ███████░░░ Moderate
└ Scientific impact: ███████░░░ Moderate
🔗 Read study
Sent by Purrptide Signal · purrptide.com/news